SWTX logo

SpringWorks Therapeutics (SWTX) Company Overview

Profile

Full Name:

SpringWorks Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

September 13, 2019

Indexes:

Not included

Description:

SpringWorks Therapeutics, Inc. is a biopharmaceutical company operating in the clinical stage. The company is focused on acquiring, developing, and commercializing medicines for patients suffering from rare diseases and oncological diseases. The company has a portfolio of oncology product candidates targeting small molecules, and other programs aimed at treating genetically defined types of cancer. It provides nirogacestat, which is an oral small molecule gamma-secretase inhibitor (GSI). It also provides mirdametinib, which is an oral low molecular weight MEK inhibitor. Mirdametinib is being developed for the treatment of plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN). SpringWorks Therapeutics, Inc. was founded in 2017, with its headquarters located in Stamford, Connecticut.

Events Calendar

Earnings

Next earnings date:

Feb 20, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 8, 25 Guggenheim
Buy
Nov 20, 24 Evercore ISI Group
Outperform
Nov 12, 24 HC Wainwright & Co.
Buy
Sep 4, 24 JP Morgan
Overweight
Aug 28, 24 HC Wainwright & Co.
Buy
Jun 4, 24 HC Wainwright & Co.
Buy
May 31, 24 HC Wainwright & Co.
Buy
May 6, 24 HC Wainwright & Co.
Buy
Mar 6, 24 JP Morgan
Overweight
Mar 6, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
SWTX
zacks.comJanuary 14, 2025

SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.

SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
SWTX
seekingalpha.comJanuary 13, 2025

SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025.

Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
SWTX
zacks.comJanuary 8, 2025

SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
SWTX
seekingalpha.comDecember 31, 2024

SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting.

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
SWTX
seekingalpha.comDecember 15, 2024

Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
SWTX
zacks.comDecember 12, 2024

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?

Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect?
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect?
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect?
SWTX
zacks.comNovember 14, 2024

The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
SWTX
zacks.comNovember 13, 2024

SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
SWTX
seekingalpha.comNovember 12, 2024

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participants Anupam Rama - JPMorgan Peter Lawson - Barclays Corinne Johnson - Goldman Sachs David Nierengarten - Wedbush Securities Alec Stranahan - Bank of America Operator Good morning. My name is Tanya, and I will be your conference operator today.

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
SWTX
globenewswire.comNovember 12, 2024

STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET.

FAQ

  • What is the ticker symbol for SpringWorks Therapeutics?
  • Does SpringWorks Therapeutics pay dividends?
  • What sector is SpringWorks Therapeutics in?
  • What industry is SpringWorks Therapeutics in?
  • What country is SpringWorks Therapeutics based in?
  • When did SpringWorks Therapeutics go public?
  • Is SpringWorks Therapeutics in the S&P 500?
  • Is SpringWorks Therapeutics in the NASDAQ 100?
  • Is SpringWorks Therapeutics in the Dow Jones?
  • When was SpringWorks Therapeutics's last earnings report?
  • When does SpringWorks Therapeutics report earnings?
  • Should I buy SpringWorks Therapeutics stock now?

What is the ticker symbol for SpringWorks Therapeutics?

The ticker symbol for SpringWorks Therapeutics is NASDAQ:SWTX

Does SpringWorks Therapeutics pay dividends?

No, SpringWorks Therapeutics does not pay dividends

What sector is SpringWorks Therapeutics in?

SpringWorks Therapeutics is in the Healthcare sector

What industry is SpringWorks Therapeutics in?

SpringWorks Therapeutics is in the Biotechnology industry

What country is SpringWorks Therapeutics based in?

SpringWorks Therapeutics is headquartered in United States

When did SpringWorks Therapeutics go public?

SpringWorks Therapeutics's initial public offering (IPO) was on September 13, 2019

Is SpringWorks Therapeutics in the S&P 500?

No, SpringWorks Therapeutics is not included in the S&P 500 index

Is SpringWorks Therapeutics in the NASDAQ 100?

No, SpringWorks Therapeutics is not included in the NASDAQ 100 index

Is SpringWorks Therapeutics in the Dow Jones?

No, SpringWorks Therapeutics is not included in the Dow Jones index

When was SpringWorks Therapeutics's last earnings report?

SpringWorks Therapeutics's most recent earnings report was on Nov 12, 2024

When does SpringWorks Therapeutics report earnings?

The next expected earnings date for SpringWorks Therapeutics is Feb 20, 2025

Should I buy SpringWorks Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions